Kornimate/medical-research-clean huggingface dataset:
salvage docetaxel for pretreated urothelial cancer

Conditions: Bladder Cancer

Summary: based on the previous clinical experience in other cancers, and considering the absence of current standard salvage regimens, the single agent docetaxel is selected as the regimen for this phase ii study. main toxicity of docetaxel is myelosuppression. the low rate of severe myelosuppression observed in other cancer trials warrants further study in urothelial cancer. the objective of the study is to evaluate the safety and activity of weekly docetaxel given as salvage therapy for advanced urothelial cancer.

study scheme patients eligible for this study will be offered participation. screening numbers are endowed to all subjects who sign the informed consent forms. these screening numbers are used as 'subject identification code" along with subject initials. subjects withdrawn from the study retain their screening number. patients will have study drug discontinued at the time of progression and will then remain on study for a 4-week safety follow-up. those without progression may continue to receive docetaxel as long as this is considered to be in their interest by their physician. after progression, patients will remain on study for the purpose of collecting follow-up and survival information. vii-3. study treatment the study drug doses should be calculated taking the body surface area into consideration. docetaxel 30 mg/m2 will be administered on days 1 and 8 every 3 weeks. docetaxel will be diluted in 250 ml 0.9% saline or 5% dextrose to produce a final solution with concentration of 0.3-0.74 mg/ml. it will be administered as an infusion over 60 min on each infusion day. patients will be premedicated with iv dexamethasone 15 mg, antihistamines and a prophylactic antiemetic treatment prior to docetaxel infusion in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. patients experiencing adverse events attributed to irinotecan should have treatment delay as needed and/or may be interrupted or reduced depending on individual tolerability and according to the protocol. treatment will be continued until disease progression, unacceptable toxicities, or consent withdrawal. after failure of study treatment, further treatment can be administered at the discretion of investigators.

Eligibility criteria:
inclusion criteria: * aged over 20 years or older * histologically confirmed metastatic and/or unresectable urothelial carcinoma arising from bladder, ureter, or renal pelvis * ecog performance status of 0 or 1 * measurable disease, or evaluable lesion(s), as defined by recist * clinical failure of the prior chemotherapy for advanced disease, including gemcitabine and platinum * adequate major organ functions * written informed consent exclusion criteria: * severe co-morbid illness and/or active infections * prior treatment with taxanes (paclitaxel and docetaxel) * any patients judged by the investigator to be unfit to participate in the study
validation of an electroencephalograph based algorithm for detection of onset and deterioration of acute ischemic stroke by comparison to nihss

Conditions: Stroke

Summary: the purpose of this study is the validation of an electroencephalograph based algorithm for detection of onset and deterioration of acute ischemic stroke by comparison to nihss.

inclusion criteria study population 1. age \> 18 years old. 2. acute stroke symptoms onset within 2 weeks of inclusion, and as proximate to event as possible and as long as there was no neurological deterioration (δnihss\>4) from symptoms onset to inclusion. 3. patients with tia lasting at least 5 minutes or minor acute ischemic stroke (nihss \< 4 at the time of enrolment) 4. more than 3 of the following: blood pressure \>140/90 or unknown, irregular heartbeat, atrial fibrillation, smoker, cholesterol \>240 or unknown, has diabetes, lack of physical exercise, overweight, has stroke in the family or between 4 and 6 of the following: blood pressure 120-139/80-89, unknown irregular heartbeat, atrial fibrillation, trying to quit smoking, cholesterol 200-239, borderline diabetes, some exercise, slightly overweight, not sure if stroke occurred in family exclusion criteria study population 1. intracranial hemorrhage on admission by ct. 2. previous major hemispheric stroke. 3. patients with pure sensory symptoms, 4. significant movement disorder. 5. local skull or skin affliction which prevents sensor application. 6. any known condition which in the opinion of the investigator may interfere with the protocol implementation.

Eligibility criteria:
inclusion criteria study population 1. age \> 18 years old. 2. acute stroke symptoms onset within 2 weeks of inclusion, and as proximate to event as possible and as long as there was no neurological deterioration (δnihss\>4) from symptoms onset to inclusion. 3. patients with tia lasting at least 5 minutes or minor acute ischemic stroke (nihss \< 4 at the time of enrolment) 4. more than 3 of the following: blood pressure \>140/90 or unknown, irregular heartbeat, atrial fibrillation, smoker, cholesterol \>240 or unknown, has diabetes, lack of physical exercise, overweight, has stroke in the family or between 4 and 6 of the following: blood pressure 120-139/80-89, unknown irregular heartbeat, atrial fibrillation, trying to quit smoking, cholesterol 200-239, borderline diabetes, some exercise, slightly overweight, not sure if stroke occurred in family exclusion criteria study population 1. intracranial hemorrhage on admission by ct. 2. previous major hemispheric stroke. 3. patients with pure sensory symptoms, 4. significant movement disorder. 5. local skull or skin affliction which prevents sensor application. 6. any known condition which in the opinion of the investigator may interfere with the protocol implementation.

Keywords: stroke
evaluating mutations in met and tp53 among patients diagnosed with squamous cell carcinoma

Conditions: Squamous Cell Carcinoma of the Lung; Squamous Cell Carcinoma of the Head and Neck

Summary: this study focuses on advanced lung and head and neck scc tumours, with adjacent normal lung tissues. biopsies will be performed in national university health system, singapore (nuhs) as part of participants' standard care. patient blood was also required for extraction of cell free dna (cfdna) and genomic dna (gdna). patients' medical records will also be reviewed for the purpose of this study.

primary objective: to investigate the prevalence of met and tp53 mutations, as well as her2 and met amplification, in lung and head and neck tumours, through prospective collection of tumour specimens in newly recruited patients. secondary objectives: 1. to distinguish the presence of somatic/germline met and tp53 mutation in lung and head and neck tumours. 2. to detect for amplifications of met and/or her2 genes in scc samples. 3. to investigate the association and interaction of cmet and her2 in scc tumours. 4. to establish a prospective documation of clinical, histopathological, treatment and follow-up (clinic pathological) data of newly recruited patients.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region 3. no other active malignancy within the past 24 months 4. refractory disease exclusion criteria: 1. patient with other active malignancy within the past 24 months 2. unable or unwilling to provide signed informed consent

Keywords: mutations in met and tp53
ice-sense™ cryotherapy for breast fibroadenoma trial

Conditions: Fibroadenoma

Summary: the purpose of this study is to determine whether the ice-sense, a novel cryotherapy system (a system that freezes tissues), is safe and effective in the treatment of benign breast tumors such as fibroadenoma.


Eligibility criteria:
inclusion criteria: * patient is above 18 years old. * patient has breast fibroadenoma, proven by biopsy (core biopsy). * patient's fibroadenoma can be visualized with ultrasound. * patient's fibroadenoma size is between 0.5cm and 3cm at its largest dimension. * patient is able to visit the clinic as needed during the 12-month follow-up period following the cryoablation procedure. * the patient has been informed of the study and agrees to its provisions, and has signed an irb/ec approved written informed consent, including data privacy authorization. exclusion criteria: * patients with history of breast cancer. * women with known pregnancy. * patients with superficial fibroadenoma very close to the skin. * patient has undergone major surgery within the previous 12 weeks. * patients with any terminal illness, or with a life expectancy \<2 year. * patients carrying contagious diseases such as tuberculosis hepatitis or aids. * patient participating in other trials using drugs or devices.
effectiveness of dn versus tu along with routine pt in patients with for chronic neck pain rct

Conditions: Neck Pain

Summary: to determine the effectiveness of dry needling and therapeutic ultrasound for the treatment of chronic neck pain


Eligibility criteria:
inclusion criteria: * the inclusion criteria will be office workers having pain sensation at neck for at least 4 months * pain for 3-7 on nrs and with the limited or painful rom. * age of the participants will be 20-35 years. * only those individuals will be included who are working in the field for more than 8 months and work for 6-8 hours per day. exclusion criteria: * the exclusion criteria were any other neurological conditions of cervical vertebra, cervical radiculopathy, any vascular disease, tumors or any other local infection
effects of electrical muscle stimulation on waist circumference in adults

Conditions: Abdominal Obesity

Summary: this randomized, placebo-controlled, double-blind, controlled study was designed to investigate the efficacy of electrical muscle simulation (ems) for treatment of waist circumference (wc) reduction in abdominal obese adults. 60 patients with abdominal obese, man with wc \> 90 cm and woman with wc \> 80 cm, received ems as experimental group (eg) or transcutaneous electrical nerve stimulation (tens) as control group (cg) 5 times a week for 12 weeks.

background: this randomized, placebo-controlled, double-blind, controlled study was designed to investigate the efficacy of electrical muscle simulation (ems) for treatment of waist circumference (wc) reduction in abdominal obese adults. methods: 60 patients with abdominal obese, man with wc \> 90 cm and woman with wc \> 80 cm, received ems as experimental group (eg) or transcutaneous electrical nerve stimulation (tens) as control group (cg) 5 times a week for 12 weeks.

Eligibility criteria:
inclusion criteria: * subject has abdominal obese seventy subjects between the age 18 and 65 years * abdominal obesity was defined as having a waist circumference (wc) \>90 cm for men or wc \>80 cm for women was defined based on the asia-pacific criteria of the international diabetes federation. exclusion criteria: * pregnant or breastfeeding, had taken any treatment for weight loss or any medication known to affect weight * had a weight loss of 3% or more in the preceding 3 months, had undergone any major surgery during the 1 year prior to study commencement * had any inserted metallic materials including a pacemaker. * aspartate aminotransferase or alanine aminotransferase of 100 mg/dl or more * serum creatinine of 1.5 mg/dl or more * a history of coronary arterial disease or cerebrovascular disease, impairment of a major organ system, cancer, severe lung diseases, severe cerebral trauma, uncontrolled hypertension and psychiatric diseases including eating disorder, etc.
outside the cage (otc) robotic lobectomy

Conditions: Lung Cancer Stage I

Summary: this study consists in a prospective pilot study evaluating the feasibility and safety of otc rats lobectomies in patients treated for lung cancer. all patients with clinical stage i tumors (≤ct2n0m0) planned to undergo a vats or rats lobectomy at the chum will be approached. at our institution, lobectomies are either performed open by thoracotomy or by mis, including vats and rats. the technique is selected based on tumor size, tumor location and patient characteristics. only patients already planned for a vats or rats lobectomy will be approached. they will be identified through the operation request forms and will be approached either in the preoperative clinic or the day before surgery, when admitted. the investigators aim to recruit 20 patients.

consenting patients will undergo lobectomy by otc rats following the exact standard steps usually done by vats/rats, aside from the ports that will be placed in the subcostal plane. the characteristics of both the patient and the case, will determine the number of incisions from 1-4. the davinci xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. a 24 fr soft chest tube will be left in place, as in the standard vats/rats lobectomy procedure. the incision closure will be done in a standard manner. enrolled patients will receive standard postoperative care. chest tube removal and discharge will be decided by the treating surgeon, following the same criteria as vats/rats lobectomies. images and videos will be recorded during the procedure. the postoperative course will be monitored in case of potential complications up to the 30-day follow-up appointment. medical records will be verified to obtain postoperative outcomes at follow-up appointments at the surgical clinic. all data pertaining to the 1-year follow-up will be collected and analysed retrospectively. chronic pain of otc rats lobectomy patients will be compared to that of vats lobectomy patients, for which the data will also be collected and analysed retrospectively. a propensity match score will be conducted using the two groups of patients, divided by surgical approach, to adequately interpret the degree of chronic pain experienced by patients who have received surgery using an otc approach versus the current minimally invasive thoracic approach.

Eligibility criteria:
inclusion criteria: * all patients with clinical stage i tumors (≤ct2n0m0) planned to undergo a lobectomy by vats/rats at the chum exclusion criteria: * age \< 18 years old * inability to consent to the study * pregnancy

Keywords: out of the cage lobectomy robotic
hypertensive urgency treatment and outcomes in a northeast thai population

Conditions: Hypertension on Emergence

Summary: previous studies have reported a high prevalence of hypertensive (ht) urgency. however, these studies have also reported low rates of serious complications, suggesting that rapid blood pressure (bp) reduction may be unnecessary. there are limited clinical data available on this topic in asian populations. the investigators aimed to determine the basic characteristics, treatment methods, and outcomes in ht urgency patients, both in the emergency room (er) and at a two-week follow-up.

previous studies have reported the high prevalence of hypertensive (ht) urgency. however, these studies have also reported low rates of serious complications, suggesting that rapid blood pressure (bp) reduction may be unnecessary. there are limited clinical data available on this topic in asian populations. the investigators aimed to determine the basic characteristics, treatment methods, and outcomes in ht urgency patients, both in the emergency room (er) and at a two-week follow-up. this was a cohort study conducted at srinagarind hospital, a tertiary-care level university hospital in khon kaen, thailand. the data collection period was from january 2012 to june 2017. the khon kaen university ethics committee in human research approved the protocol. patients aged 18 years or older who visited the er with a diagnosis of ht urgency were consecutively enrolled in the study. patients who were pregnant or lactating had secondary causes of ht, or had incomplete medical records were excluded from the study office bp was measured using an upper arm cuff oscillometric bp device. the appropriate cuff size for each individual's arm circumference was used. three bp readings were taken at 30-second intervals with the patient in a sitting position after five minutes of rest. the average of three bp measurements was used for analysis. baseline characteristic data were shown as the mean and standard deviation (sd) or percentage. an independent sample t-test was used to compare between groups for continuous variables including age, body mass index (bmi), systolic blood pressure (sbp), diastolic blood pressure (dbp), mean arterial pressure (map), time of treatment, and the number of medications being administered. a probability value \<0.05 was considered statistically significant. all statistical analyses were performed with spss for mac version 20.0, registered to khon kaen university.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older who visited the er with a diagnosis of ht urgency exclusion criteria: * pregnant or lactating * secondary hypertension
atopic dermatitis: early gene expression changes as predictors of therapeutic response to narrow-band uvb treatment

Conditions: Atopic Dermatitis

Summary: phototherapy with narrow band (nb) ultraviolet b (uvb) is a safe and effective but time consuming treatment option for patients with widespread eczema. despite efficacy we know little about how it works, and even less why some patients fail to respond. tintle et al showed that nb-uvb induced strong suppression of the th2 and th22 axes in patients with atopic dermatitis (ad), and also normalized the epidermal barrier function. we want to map the very early changes in gene expression after uvb-treatment in order to shed light on disease mechanisms, which eventually could lead to better treatment options.

patients will be scored with patient-oriented eczema measure (poem), eczema area and severity index (easi), scorad (scoring atopic dermatitis) and dermatology life quality index (dlqi) to assess disease severity. the investigators will measure trans epidermal water loss (tewl), take bacterial swabs for analysis of the microbiome and culture for staphylococcus aureus and test for mutations in the filaggrin-gene by sputum samples. blood serum samples will be taken to measure serum (s) -immunoglobulin e, s-vitamin d status, full blood count including white cell differential and different cytokines. any history of allergic asthma, allergic rhinitis or food allergy will be noted as well as any recent history of sun exposure, use of tanning beds or uvb-therapy. the suberythemal dose of uvb for each patient will be established. in each patient two contralateral areas (e.g. both underarms) with eczema will be chosen, which are as similar as possible regarding distribution and severity. one area will be biopsied with a 4mm punch followed by locally treatment with nb-uvb (311nm) three times. in this way the untreated side will serve as an internal control. both sides will be biopsied after these initial three rounds of treatment. the patients will then undergo 24 standard full-body nb-uv-treatment sessions followed by a new biopsy of the same area. skin from non-lesional sun-protected skin from nates will also be samples prior to and after uvb-treatment.

Eligibility criteria:
inclusion criteria: * atopic dermatitis exclusion criteria: * other inflammatory skin disease * concurrent illness
a study of imr-687 in adult participants with sickle cell anemia (homozygous hbss or sickle-β0 thalassemia)

Conditions: Sickle Cell Disease

Summary: study of imr-687 in adult participants with sickle cell anemia (sca) (homozygous hbss or sickle-β0 thalassemia).

this is a proof-of-concept study in adult sca participants, ages 18 to 55 years old, to examine the safety, tolerability, and pharmacokinetic (pk), as well as the potential pharmacodynamic (pd) effects and clinical efficacy, of imr-687 across a range of doses. imr-687 was administered in 2 populations of participants with sca: those who were not receiving hydroxyurea (hu) and those who were receiving a stable dose of hu according to standard of care.

Eligibility criteria:
key inclusion criteria: * male or female participants with confirmed sca * age 18 to 55 years, inclusive * for participants on hu, must have been on a stable dose for at least 60 days prior to screening key exclusion criteria: * total hemoglobin \>12.5 or \<6 grams/deciliter * red blood cell transfusion within 60 days of baseline * \>7 hospitalizations for vaso-occlusive crises (vocs) within the last year * estimated glomerular filtration rate \<50 milliliter/minute * aspartate aminotransferase/alanine aminotransferase \>3x the upper limit of normal
physical activity for improving quality of life and reducing frailty in advanced age

Conditions: Aging

Summary: individuals of advanced age undergo both physical and cognitive deterioration. the aim of this study is to explore the connection between level of physical activity and health parameters, quality of life, and frailty.


Eligibility criteria:
inclusion criteria: * age above 65 * able to undergo graded stress exam exclusion criteria: * all others